Severity of liver fibrosis predictor of CVD in type 2 diabetes: Study

According to the World Health Organization, cardiovascular disease (CVD) remains the leading cause of death worldwide, accounting for approximately 18 million deaths per year. Nevertheless, the worldwide prevalence of metabolic diseases, such as type 2 diabetes mellitus, obesity, and non-alcoholic fatty liver disease (NAFLD), also known to be common risk factors for CVD, has dramatically increased over the last decades. Compared with nondiabetic subjects, people with type 2 diabetes appear to have an increased risk of developing NAFLD and certainly have a higher risk of developing fibrosis and cirrhosis. Several mechanisms have been suggested to be responsible for associating FLD with CVD through several mechanisms including low-grade systemic inflammation, oxidative stress, adipokines, endoplasmic reticulum stress, lipotoxicity and microbiota dysbiosis which may also be influenced by other factors such as genetic and epigenetic variations. Despite all this evidence, the association of Liver fibrosis and CVD in T2D patients are not fully elucidated and much remains unknown. For this purpose, researchers of the Yonsei University College of Medicine, Seoul, Republic of Korea, conducted a study to assess whether liver fibrosis predicted the risk of CVD in patients with T2D.

It was a retrospective observational study of 1,481 patients who had commenced oral anti‐diabetic drugs to treat newly diagnosed T2D between 2006 and 2010. Researchers used the fibrosis‐4 index (FIB‐4), non‐alcoholic fatty liver disease fibrosis score (NFS), and BARD score to assess the fibrotic burden at the time of T2D diagnosis.

Key findings of the study were:

♦Researchers noted 242 (16.3%) patients developed CVD during the follow‐up period of median 88.1 months.